Clinuvel Pharmaceuticals (CUV: $15.51) is continuing to expand the applications for its core therapeutic, afamelanotide (Scenesse for the treatment of EPP). In preclinical models it has been shown that afamelanotide can have a positive impact on neurological conditions, including Parkinson's disease.

Eli Lilly has received FDA approval for donanemab (Kisunla) for the treatment of early-stage Alzheimer's disease. It joins Leqembi from Eisai/Biogen as the first effective, disease modifying treatments for the disease.

Radiopharm Theranostics (RAD: $0.043), a radiopharmaceutical therapeutic-diagnostic company focusing on a range of cancers, has announced an institutional placement of $70 million.

Neuren Pharmaceuticals (NEU: $19.02) announced top-line results for its phase II trial of drug candidate NNZ-2591 in 16 patients with Pitt-Hopkins Syndrome (PTHS).

At this year's AGM held recently, the chairman of Anteris Technologies (AVR: $19.05) John Seaberg said that after 45 years of working in the cardiovascular field, he has never seen a device with as much potential as the DurAVR aortic valve.

Dimerix (DXB: $0.56) announced an exclusive license agreement with Taiba to commercialise DMX-200 in seven Middle Eastern countries.

Blinklab (BB1: $0.382) which listed on the ASX last month at $0.20, may have easily gone down the VC funding route, with interest at the same time from the US venture capital sector.

Company: Blinklab

Issue Price: $0.20

Funds to be raised: $7 million

ASX code: BB1

Lead Manager: Westar Capital (not underwritten)

Offer closes: 21 March 2024

Expected listing date: 4 April 2024

Market capitalisation on listing: $20 million

Dimerix - Interim Data Assessment in Mid-March

Last month, Neuren Pharmaceuticals (NEU; $24.65) announced impressive top-line data from its Phase II trial of NNZ-2591 conducted in 18 patients with Phelan-McDermid Syndrome (PMS).